Batch 001 - Live Allocation

Next Release: Aug 2026

Vivre Labs

Institutional Longevity

Catalogue
Single-vial Blends · one injection
Clinical Details

- Peptides -

- Single-vial Blends -

- Goals -

- Clinical Reference -

- Guides -

- Integrity -

◇ Compound Reference

IMMUNOMODULATORApproved (Intl)Popular · Immune Support

Thymosin Alpha-1

Immune Regulator · 10mg

Status

Approved (Intl)

Route

SubQ

Half-life

~2 hours plasma

Class

Thymic peptide

MechanismT-Cell Maturation & Activation

Cohort61 active prescriptions

Educational reference only - not a prescription or dosing recommendation. Some compounds are investigational or used off-label; suitability, dose, and monitoring are determined by your supervising physician. See Informed Consent & Disclaimer.

V-Series Member

$105 USD/vial

À-la-carte: $115 USD/vial · Save 9%

Vials per allocation

Member total (1×)$105

À-la-carte total$115

Flat per-vial pricing. Quantity is allocated and dispensed within your physician-supervised protocol - not a direct sale.

What this is

Immune system regulator supporting T-cell function and innate immunity. Applications in chronic infection and immunosenescence.

Immune Regulator · 10mg per vial · dispensed after a physician review.

◇

Janoshik Verified

HPLC + MS purity, every batch

Independent third-party lab

⬡

COA Per Batch

Lot-level certificates published

Labeled vs actual mg disclosed

⊙

Protocol Reviewed

Used in V-Series clinical stacks

Phase 1 supervision onboarding

Used inV-Series

V-05

Calm - Inflammation & Gut

Popular · Immune & Inflammation

Thymosin Alpha-1 · Immunomodulator

◆ Certificate of Analysis · Thymosin Alpha-1

JANOSHIK ANALYTICALHPLC + MS · Independent third-party

DEMO

Lot · VL-TA1-2026-03A

99.67%

Labeled

5 mg

Actual (HPLC)

5.18 mg

Method

HPLC + MS

Tested

Mar 30, 2026

Endotoxin

not tested for this lot

Heavy metals

not tested for this lot

◉

Clinical Overview

Thymosin Alpha-1

Thymosin Alpha-1 is a 28-amino-acid peptide hormone naturally produced by the thymus gland. Approved for clinical use in over 35 countries (notably for chronic hepatitis B and C, and as adjunct cancer therapy).

Acts as a key immune system regulator.

◈

Immune Modulation

Modulates T-cell maturation and innate immunity.

❖

Immune Balance

Increases helper T-cell and NK-cell activity.

✦

Approval Abroad

Approved in some countries; off-label in the US.

◈

Mechanism

How It Works

Modulates T-cell maturation, dendritic cell function, and innate immunity. Increases helper T-cell production and Natural Killer cell activity.

Particularly relevant in age-related immune decline (immunosenescence).

Mechanism & evidence - the honest frame

Mechanism & evidence: Thymosin alpha-1 (thymalfasin; historically marketed as Zadaxin) is an immunomodulator that promotes T-cell maturation, enhances regulatory T-cells and balances Th1/Th17 responses, acting partly through dendritic-cell signalling. Strongest oncology signal is a phase-2 setting: adding Tα1 to dacarbazine in stage-IV melanoma produced more confirmed responses than chemotherapy alone (Maio et al., J Clin Oncol 2010) - a positive phase-2 signal in small numbers, not a practice-changing phase-3 result. Approved abroad as an adjuvant in hepatitis B/C and certain cancers; US availability is off-label. Sepsis/infectious-disease data remain mixed.

✚

Patient Bloodwork Guide

Bloodwork for Recovery & Repair Protocols

Tissue repair / anti-inflammatory - BPC-157, TB-500, KPV, Thymosin, V-01, V-05

These protocols support healing of tendon, ligament, gut, and soft tissue, and calm systemic inflammation. Monitoring tracks inflammation coming down and confirms the body is recovering rather than being strained.

Incremental approach. Vivre uses conservative, course-based dosing - often a defined repair window rather than indefinite use. Markers and imaging confirm progress before extending.

Inflammation

hs-CRPA sensitive marker of systemic inflammation - the key “is it calming down” signal.

IL-6An inflammatory messenger; tracked alongside hs-CRP.

ESRA classic inflammation marker for the bigger picture.

Healing confirmation

Imaging (ultrasound)For tendon/ligament work - confirms structural healing, not just how you feel.

Immune markers (CD4/CD8)Where immune modulation (e.g. Thymosin) is part of the protocol.

Overall safety

CBC & CMPStandard blood count, liver, and kidney panels.

When the tests happen

Baselinehs-CRP, IL-6, ESR + imaging of the target area.

Weeks 4 / 8 / 12hs-CRP, IL-6, ESR - track inflammation trend.

Week 12Repeat imaging to confirm structural healing.

Educational only - not medical advice or a dosing instruction. Your physician orders the tests, sets your dose, interprets results, and decides if a protocol is right for you. See the Informed Consent & Disclaimer for full terms.

⊞

Technical Profile

Measurable Properties

Class	Thymosin α1 (28 aa immunomodulatory peptide)
Mechanism	T-cell function modulation; innate/adaptive immune signalling - characterised
Terminal half-life	Short (~2 hours order)
Metabolism	Peptidase degradation
Evidence base	Moderate-to-strong; approved for certain indications in some jurisdictions
Regulatory status	Approved in some markets for specific uses; otherwise physician-supervised only

Certificate of Analysis (per batch)

Analytical method: UHPLC-MS. Batch COA available on request - link to be populated per shipment.

COA link - pending per batch

Immunopharmacology reasonably characterised; approval varies by market. Educational only.

Clinical Literature

Peer-Reviewed References

Thymosin Alpha-1: A Comprehensive Review of the Literature

King R, Tuthill C · 2016 · International Immunopharmacology 2016;33:9–14

▾

Findings

Review of clinical and mechanistic literature on Thymosin alpha-1, summarising trial data across chronic hepatitis, vaccine adjuvant use, and immune-modulating contexts. The compound is approved in multiple jurisdictions for specific indications; broad anti-aging or general-immunity claims outside those indications are not supported by the controlled trial evidence.

View on publisher ↗

Thymosin alpha-1 has trial-supported approvals for specific indications in some markets. Use beyond approved indications is off-label and physician-supervised.

◇

Clinical Applications

Indications

Chronic viral infection adjunct
Immunosenescence
Cancer therapy adjunct (with oncologist oversight)
Chronic immune dysregulation

⊙

Pharmacokinetics

Half-Life & Duration of Action

Half-life is how long a compound stays at active plasma concentration in your body. Most peptides in this catalogue have short plasma half-lives - they clear from your bloodstream within hours, sometimes minutes. The long-half-life compounds in this catalogue are the approved-class incretins (Tirzepatide, Semaglutide, Retatrutide), which are designed for once-weekly dosing - that's the molecular engineering choice that makes weekly dosing work.

Plasma Half-Life

~2 hours plasma. Immune-modulating effects on T-cell and innate immune function persist longer through downstream immunological signaling.

Why this matters for you

If you don't tolerate a compound or need to discontinue a protocol, short-half-life peptides are out of your bloodstream within hours - not days or weeks. That said, the biological effects they initiate (tissue repair signalling, mitochondrial signalling, gene expression changes) often persist longer than the peptide itself, through downstream cellular cascades. This is normal peptide pharmacology and is important context - the molecule clears fast, but the biology takes longer to wind down.

Evidence Base

Approved in many countries. Established clinical safety profile. Limited US FDA approval but available through compounding.

Dosing protocols, administration frequency, and titration schedules are physician-determined at consultation - not published on these public pages. Vivre maintains a separate internal clinical reference for treating physicians.

▣

Featured In

V-Series Protocols Including Thymosin Alpha-1

◎

Commonly Paired

Compounds Often Prescribed With Thymosin Alpha-1

Clinical co-allocation patterns observed in Vivre's allocation history. Pairings are not prescriptions - the physician determines suitability per patient at consultation.

Cytoprotective Peptide

BPC-157

Base Form · 5mg

◆ immune + repair

Thymosin α1's immune-modulating activity pairs with BPC-157's regenerative signal in protocols where immunological dysregulation underlies impaired healing.

View BPC-157 detail →

READY TO PROCEED

Start with the Biological Audit

Thymosin Alpha-1 is verified and lot-tested, dispensed following a Biological Audit. The Audit is complimentary for the Batch 001 cohort.

$105 USD/vial

Thymosin Alpha-1 · Member rate